# Vascular targeted photodynamic tx aids low-risk prostate cancer

July 25 2017

(HealthDay)—For men with low-risk prostate cancer, vascular targeted

photodynamic therapy achieves an 82 percent rate of absent clinically significant cancer in treated lobes, according to a study published in the August issue of *The Journal of Urology*.

Souhil Lebdai, M.D., from the University Hospital of Angers in France, and colleagues followed 82 men treated with vascular targeted photodynamic therapy for low-risk prostate cancer every six months. Six months after treatment or when there was biological or clinical progression, patients underwent prostate biopsies.

Patients were followed for a median of 68 months. The researchers found that median progression-free survival was 86 months. Six months after treatment, there was a significant 41 percent decrease in median prostate-specific antigen, which remained stable during follow-up (P

"Padeliporfin vascular targeted photodynamic therapy for low-risk prostate cancer achieved an 82 percent rate of absent clinically significant cancer in treated lobes and 76 percent of patients avoided radical therapy at a median follow-up of 68 months," the authors write. "However, longer term follow-up is required to determine long-term outcomes."

One author disclosed financial ties to Steba Biotech, which funded the study.

More information: Abstract
Full Text

Citation: Vascular targeted photodynamic tx aids low-risk prostate cancer (2017, July 25) retrieved 30 June 2024 from https://medicalxpress.com/news/2017-07-vascular-photodynamic-tx-aids-low-risk.html